TICKERNOMICS Sign up
Last Update: 2024-03-28 02:18:26
Diaceutics PLC ( DXRX.LSE ) https://www.diaceutics.com
1.31USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
DXRX.LSE
3.20%
SPY
32.74%
-8.57%
DXRX.LSE
SPY
92.93%
-4.30%
DXRX.LSE
SPY
224.41%
DXRX.LSE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
110.69
88.05
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
547.77
3.82
2.13
1.41
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-3.23
-5.45
0.00
Other Earnings and Cash Flow Stats:
Diaceutics PLC ( DXRX.LSE ) Net Income TTM ($MM) is 0.00
Diaceutics PLC ( DXRX.LSE ) Operating Income TTM ($MM) is 0.00
Diaceutics PLC ( DXRX.LSE ) Owners' Earnings Annual ($MM) is 2.74
Diaceutics PLC ( DXRX.LSE ) Current Price to Owners' Earnings ratio is 40.36
Diaceutics PLC ( DXRX.LSE ) EBITDA TTM ($MM) is 0.00
Diaceutics PLC ( DXRX.LSE ) EBITDA Margin is 0.00%
Capital Allocation:
Diaceutics PLC ( DXRX.LSE ) has paid 0.00 dividends per share and bought back 1.61709 million shares in the past 12 months
Diaceutics PLC ( DXRX.LSE ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Diaceutics PLC ( DXRX.LSE ) Interest-bearing Debt ($MM) as of last quarter is 0
Diaceutics PLC ( DXRX.LSE ) Annual Working Capital Investments ($MM) are 0
Diaceutics PLC ( DXRX.LSE ) Book Value ($MM) as of last quarter is 51
Diaceutics PLC ( DXRX.LSE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Diaceutics PLC ( DXRX.LSE ) has 22 million in cash on hand as of last quarter
Diaceutics PLC ( DXRX.LSE ) has 4 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Diaceutics PLC ( DXRX.LSE ) has 84 common shares outstanding as of last quarter
Diaceutics PLC ( DXRX.LSE ) has 0 million USD of preferred stock value
Academic Scores:
Diaceutics PLC ( DXRX.LSE ) Altman Z-Score is 11.12 as of last quarter
Diaceutics PLC ( DXRX.LSE ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Diaceutics PLC ( DXRX.LSE ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Diaceutics PLC ( DXRX.LSE ) for the amount of $ on
46.10% of Diaceutics PLC ( DXRX.LSE ) is held by insiders, and 63.64% is held by institutions
Diaceutics PLC ( DXRX.LSE ) went public on 1970-01-01
Other Diaceutics PLC ( DXRX.LSE ) financial metrics:
FCF:4.51
Unlevered Free Cash Flow:-2.22
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:0.00
Buffet's Owners Earnings:2.74
Price to Owner's Earnings:40.36
About Diaceutics PLC ( DXRX.LSE ) :
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.